Beijing Kawin Technology Share-Holding Co., Ltd. (SHA:688687)
16.41
+0.53 (3.34%)
Nov 5, 2026, 3:00 PM CST
SHA:688687 Revenue
Beijing Kawin Technology Share-Holding had revenue of 339.00M CNY in the quarter ending September 30, 2026, a decrease of -5.94%. This brings the company's total for the last twelve months to 1.21B, up 5.51% year-over-year. In the year 2025, Beijing Kawin Technology Share-Holding had annual revenue of 1.32B with 7.35% growth. That makes Beijing Kawin Technology Share-Holding the 18,176th largest company in the world by revenue and 3,320th in China.
Revenue (ttm)
1.21B
Revenue Growth
+5.51%
P/S Ratio
2.27
Revenue / Employee
2.01M
Employees
601
Market Cap
2.75B
Revenue by Geography
- Central China 282.28M 21.4%
- Southern China 263.94M 20.0%
- Southwest China 227.04M 17.2%
- Northwestern China 198.21M 15.0%
- East China 181.03M 13.7%
- North China 91.19M 6.9%
- Northeast China 69.99M 5.3%
- Overseas 7.10M 0.5%
Fiscal year ended Dec 31, 2025 See the full SHA:688687 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.32B | 90.49M | 7.35% |
| Dec 31, 2024 | 1.23B | -181.71M | -12.87% |
| Dec 31, 2023 | 1.41B | 252.03M | 21.73% |
| Dec 31, 2022 | 1.16B | 15.62M | 1.36% |
| Dec 31, 2021 | 1.14B | 282.30M | 32.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Qingdao Vland Biotech INC. | 1.45B |
| Shanghai Universal Biotech | 1.22B |
| Guangdong VTR Bio-Tech | 827.06M |
| Landfar Bio-medicine | 748.74M |
| Hubei Goto Biopharm Group | 665.71M |
| Zhejiang Shouxiangu Pharmaceutical | 590.94M |
| Lifecome Biochemistry | 453.12M |
| Guanhao Biotech | 344.85M |